License AgreementLicense Agreement • November 3rd, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations • New York
This License Agreement is entered as of the Execution Date (as defined below), with certain provisions that go into effect as of the Effective Date (as defined below),
AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • November 3rd, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
This Amendment No. 2 to Asset Purchase Agreement (this “Amendment No. 2”) is dated as of August 2, 2022 (the “Amendment No. 2 Effective Date”) and is made by and between Biogen MA Inc., a Massachusetts corporation (“Biogen”), and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (“Kiniksa”). Kiniksa and Biogen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Terms used in this Amendment No. 2 and not otherwise defined shall have the respective meanings set forth in the APA (as defined below).
FIFTH AMENDMENT OF SUBLEASESublease • November 3rd, 2022 • Kiniksa Pharmaceuticals, Ltd. • Pharmaceutical preparations
FIFTH AMENDMENT OF SUBLEASE (the "Fifth Sublease Amendment") made as of the 27th day of July, 2022, by and between 92 HAYDEN AVENUE TRUST, as landlord ("Landlord"), and KINIKSA PHARMACEUTICALS CORP., a Delaware corporation, as tenant (interchangeably called "Kiniksa" or "Tenant").
